Search Results for
September 01, 2023
The Revolving Door Project’s Ananya Kalahasti and Will Royce released the following statement regarding the US Chamber of Commerce’s lawsuit regarding the Inflation Reduction Act’s Medicare prescription drug negotiation program, and a financial conflict of interest regarding the judge in the Southern District of Ohio.
August 29, 2023 | The American Prospect
Who’s Running Big Pharma’s Last Stand Against Slightly Fairer Drug Pricing
One year after IRA passage, bad actors try to thwart drug price negotiation, and Biden’s efforts to defend it fall short.
June 23, 2023 | The American Prospect
Mark Rohrbaugh, a mid-level staffer at the National Institutes of Health, has consistently blocked the use of march-in rights to seize patents on high-cost drugs.
July 26, 2022
If the Walter Reed vaccine proves effective against Covid-19 and its variants in further tests, it will be a vaccine wholly created by a public institution through use of public funds. Every aspect of the vaccine production process should be widely and freely shared to ensure globally distributed manufacturing. Widespread, equitable availability of effective vaccines at truly affordable prices would go a long way in achieving your stated goal of vaccinating the world.
July 26, 2022
Advocates to President Biden: Don’t Give Away New Publicly-Owned Coronavirus Vaccine Technology to Corporations
In advance of the White House Summit on the Future of COVID-19 Vaccines today, 29 groups including Public Citizen, Demand Progress and Revolving Door Project, a project of the Center for Economic and Policy Research, sent a letter to President Joe Biden urging him to ensure that pan coronavirus vaccine technology currently under development by the U.S. military remain public, and shared with the world.
April 27, 2022 | The Lever
In his gig as a global health consultant at a powerful D.C. business strategy firm that has financial ties to one of the two major COVID-19 vaccine manufacturers, Jha has kept his client roster under wraps despite publicly promising to release a client list.
April 25, 2022 | The American Prospect
But for all of this, neither party’s congressional leaders have directly challenged the main legal mechanism that accounts for those high costs—namely, intellectual property. You’d think members of Congress would recognize the political salience of picking a fight with one of the most hated industries in America. So why isn’t anyone on Capitol Hill even talking about intellectual property’s role in driving high drug prices, and taking the PTO to task to do something about it?
December 22, 2021 | Common Dreams
The Covid-19 threat will not simply go away—especially when addressed with half measures. The administration must use its authority under the Defense Production Act much more wisely and aggressively.
October 29, 2021 | The American Prospect
Dr. Robert Califf appears to be the clearest front-runner for the (somehow) still open position of commissioner of the Food and Drug Administration. After floating his name in the press a few weeks ago, President Biden recently met with Califf in private. Such meetings tend to be the final step before a nominee is announced.
There’s just one problem: Califf is a longtime political consultant to Big Pharma and, more recently, to Big Tech. In fact, he’s so tied to those industries that he once earned the ire of a certain crucial senator from West Virginia.
October 15, 2021
Califf coordinates lobbying for major corporations — in his case, for Big Tech giants eager to get into the medical sector (and get into patients’ medical data.)